Cargando…
Patient-reported outcomes and considerations in the management of COPD: focus on aclidinium
Chronic obstructive pulmonary disease (COPD) is a complex heterogeneous disease, in which several factors combine to give the final clinical expression. Both early and more recent studies have shown that forced expiratory volume in one second (FEV(1)), despite being an extremely important parameter...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4303404/ https://www.ncbi.nlm.nih.gov/pubmed/25653503 http://dx.doi.org/10.2147/PPA.S55009 |
_version_ | 1782353937410555904 |
---|---|
author | Lopez-Campos, Jose Luis Calero, Carmen Lopez-Ramirez, Cecilia Asensio-Cruz, Maria Isabel Márquez-Martín, Eduardo Ortega-Ruiz, Francisco |
author_facet | Lopez-Campos, Jose Luis Calero, Carmen Lopez-Ramirez, Cecilia Asensio-Cruz, Maria Isabel Márquez-Martín, Eduardo Ortega-Ruiz, Francisco |
author_sort | Lopez-Campos, Jose Luis |
collection | PubMed |
description | Chronic obstructive pulmonary disease (COPD) is a complex heterogeneous disease, in which several factors combine to give the final clinical expression. Both early and more recent studies have shown that forced expiratory volume in one second (FEV(1)), despite being an extremely important parameter to predict the progression of the disease, is a poor surrogate marker for symptoms perception. Accordingly, patient-reported outcomes (PROs) have gained popularity as a measure of the impact of treatment from the patients’ perspective, since they represent the individuals’ perception of their health status, beyond any physiological limitations. Several such PROs, therefore, are currently included in multidimensional COPD evaluation. This multidimensional approach helps identify different patient types and individualize, up to a certain point, pharmacological treatment. In this multidimensional approach it is important to highlight the importance of long-acting bronchodilators in COPD treatment strategies. Long-acting bronchodilators are cost-effective and have been shown to achieve the greatest functional and clinical improvements in COPD. As a result, long-acting bronchodilators are now the main pharmacological treatment for COPD at all stages of the disease. Until recently, tiotropium was the leading bronchodilator for the treatment of COPD. The clinical development of this medication, unprecedented in inhaled therapy, involved tens of thousands of patients and yielded consistent outcomes in terms of lung function, symptoms, quality of life, exacerbations, and prognosis. However, new long-acting bronchodilators have recently been developed or are currently under development. In this review, we evaluate the effects of aclidinium bromide, a novel long-acting bronchodilator, on PROs in COPD. Aclidinium is a novel long-acting muscarinic antagonist with a good safety profile for the treatment of COPD, and has proven efficacy in both objective functional measurements and PROs. Comparison studies with tiotropium have shown it to have similar lung function improvement and a similar impact on PROs, including quality of life or symptom perception. |
format | Online Article Text |
id | pubmed-4303404 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-43034042015-02-04 Patient-reported outcomes and considerations in the management of COPD: focus on aclidinium Lopez-Campos, Jose Luis Calero, Carmen Lopez-Ramirez, Cecilia Asensio-Cruz, Maria Isabel Márquez-Martín, Eduardo Ortega-Ruiz, Francisco Patient Prefer Adherence Original Research Chronic obstructive pulmonary disease (COPD) is a complex heterogeneous disease, in which several factors combine to give the final clinical expression. Both early and more recent studies have shown that forced expiratory volume in one second (FEV(1)), despite being an extremely important parameter to predict the progression of the disease, is a poor surrogate marker for symptoms perception. Accordingly, patient-reported outcomes (PROs) have gained popularity as a measure of the impact of treatment from the patients’ perspective, since they represent the individuals’ perception of their health status, beyond any physiological limitations. Several such PROs, therefore, are currently included in multidimensional COPD evaluation. This multidimensional approach helps identify different patient types and individualize, up to a certain point, pharmacological treatment. In this multidimensional approach it is important to highlight the importance of long-acting bronchodilators in COPD treatment strategies. Long-acting bronchodilators are cost-effective and have been shown to achieve the greatest functional and clinical improvements in COPD. As a result, long-acting bronchodilators are now the main pharmacological treatment for COPD at all stages of the disease. Until recently, tiotropium was the leading bronchodilator for the treatment of COPD. The clinical development of this medication, unprecedented in inhaled therapy, involved tens of thousands of patients and yielded consistent outcomes in terms of lung function, symptoms, quality of life, exacerbations, and prognosis. However, new long-acting bronchodilators have recently been developed or are currently under development. In this review, we evaluate the effects of aclidinium bromide, a novel long-acting bronchodilator, on PROs in COPD. Aclidinium is a novel long-acting muscarinic antagonist with a good safety profile for the treatment of COPD, and has proven efficacy in both objective functional measurements and PROs. Comparison studies with tiotropium have shown it to have similar lung function improvement and a similar impact on PROs, including quality of life or symptom perception. Dove Medical Press 2015-01-17 /pmc/articles/PMC4303404/ /pubmed/25653503 http://dx.doi.org/10.2147/PPA.S55009 Text en © 2015 Lopez-Campos et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Lopez-Campos, Jose Luis Calero, Carmen Lopez-Ramirez, Cecilia Asensio-Cruz, Maria Isabel Márquez-Martín, Eduardo Ortega-Ruiz, Francisco Patient-reported outcomes and considerations in the management of COPD: focus on aclidinium |
title | Patient-reported outcomes and considerations in the management of COPD: focus on aclidinium |
title_full | Patient-reported outcomes and considerations in the management of COPD: focus on aclidinium |
title_fullStr | Patient-reported outcomes and considerations in the management of COPD: focus on aclidinium |
title_full_unstemmed | Patient-reported outcomes and considerations in the management of COPD: focus on aclidinium |
title_short | Patient-reported outcomes and considerations in the management of COPD: focus on aclidinium |
title_sort | patient-reported outcomes and considerations in the management of copd: focus on aclidinium |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4303404/ https://www.ncbi.nlm.nih.gov/pubmed/25653503 http://dx.doi.org/10.2147/PPA.S55009 |
work_keys_str_mv | AT lopezcamposjoseluis patientreportedoutcomesandconsiderationsinthemanagementofcopdfocusonaclidinium AT calerocarmen patientreportedoutcomesandconsiderationsinthemanagementofcopdfocusonaclidinium AT lopezramirezcecilia patientreportedoutcomesandconsiderationsinthemanagementofcopdfocusonaclidinium AT asensiocruzmariaisabel patientreportedoutcomesandconsiderationsinthemanagementofcopdfocusonaclidinium AT marquezmartineduardo patientreportedoutcomesandconsiderationsinthemanagementofcopdfocusonaclidinium AT ortegaruizfrancisco patientreportedoutcomesandconsiderationsinthemanagementofcopdfocusonaclidinium |